Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Financial Other
confidence 72%
filed 2026-10-19
Item 1.01
EFCAR, LLC entered into a Capital Contribution Agreement and Amendment No. 1 to a Sale and Servicing Agreement on October 13, 2026, governing capital contributions to securitization trusts (Exeter Automobile Receivables Trust 2022-5 and 2022-6) and reserve account management. While these are material definitive agreements affecting the registrant's financial obligations and securitization structure, they do not fit neatly into specific categories like debt_issuance, ma_activity, or covenant_breach; they are financial arrangements related to existing securitization vehicles rather than new debt creation or a discrete M&A event.
View raw filing on EDGAR →
8-K
Financial Other
confidence 72%
filed 2026-10-19
Item 1.01
EFCAR, LLC entered into a Capital Contribution Agreement and Amendment No. 2 to a Sale and Servicing Agreement on October 13, 2026, governing capital contributions to securitization trusts (Exeter Automobile Receivables Trust 2022-5 and 2022-6) and reserve account management. These are material financial arrangements affecting the registrant's obligations and capital structure within its securitization platform, but do not fit the specific categories of debt issuance, M&A, or other named financial events—they are structural amendments to existing securitization arrangements.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 92%
filed 2026-10-19
Item 8.01
Seneca Bancorp announced adoption of a stock repurchase program authorizing repurchase of up to 144,411 shares (approximately 8% of outstanding shares). Stock repurchases are a form of capital return to shareholders and fall within the dividend_distribution category, which encompasses "share-repurchase programs" alongside dividends and distributions. The program is material as it represents a significant capital allocation decision affecting shareholder value.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-10-19
Item 2.02
Wintrust Financial Corporation announced record net income of $700.1 million for the first nine months of 2026 and record quarterly net income of $239.1 million for Q3 2026, with detailed financial results, balance sheet metrics, and business segment performance disclosed in the attached press release and presentation. This is a standard quarterly earnings release under Item 2.02.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-10-19
Item 8.01
The filing announces the engagement of Tom Reilly, a security industry veteran, to develop and execute strategy for new integrator and distribution channels for RAD's products (RAIA, SARA, and stationary solutions). This is a strategic operational initiative focused on expanding go-to-market channels and driving revenue growth, not a traditional executive appointment to a formal officer or director role. The company explicitly states this engagement supports its goal of reaching positive operating cash flow in December 2026 by adding partner-driven revenue without adding fixed cost, making it material to investors assessing the company's path to profitability.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-10-19
EX-99.1
This is a press release announcing Q3 2026 production and sales results for Americas Gold and Silver Corporation. The exhibit discloses record consolidated silver production of 800,458 ounces, detailed production metrics by operation (Galena and Cosalá), cash balance of US$63 million, and reaffirms full-year 2026 guidance of 3.2–3.6 million ounces of silver at US$30–US$35 per ounce all-in sustaining costs. The CEO commentary and operational updates are typical of a quarterly earnings announcement. This is a discrete event disclosure of financial results, not a periodic financial report itself.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-10-19
EX-99.1
This is a quarterly production and financial results announcement for Q3 2026. The exhibit discloses Q3 2026 operational highlights (42,565 tonnes mined, 9,145 oz Au recovered at San Albino; 3,599 oz Au recovered at Moss Mine), financial highlights (total gold recovered of 12,743 oz Au with ~$50 million in revenue), and cash position ($119.3 million). The document explicitly states "Mako Mining Announces Q3 2026 Production Results" and provides detailed operating metrics, gold sales, and realized prices—the hallmark of a quarterly earnings/production release material to investors assessing operational performance and cash generation.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-10-19
Item 7.01
Charter Communications completed material transactions with Cox Communications on August 19, 2026, and is disclosing pro forma financial and operating information reflecting the Cox Transactions as if closed as of January 1, 2024. The completion of a transaction between two major cable/communications companies constitutes a material acquisition or change-of-control event that would affect a reasonable investor's assessment of the registrant's size, operations, and financial position.
View raw filing on EDGAR →
6-K
Material Litigation
confidence 92%
filed 2026-10-19
The 6-K discloses an adverse judgment against the Company's subsidiary Tongri Mechanical in a civil lawsuit brought by ICBC for approximately RMB9.75 million (principal and interest), with the Company's subsidiary bearing joint and severable liability as a guarantor. The Company has filed an appeal, which is pending. This is a material litigation event involving a significant financial obligation and represents a material adverse development that would affect a reasonable investor's assessment of the registrant's financial condition and contingent liabilities.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-10-19
EX-99.1
The exhibit announces Belite Bio's uplisting from the Nasdaq Capital Market to the Nasdaq Global Select Market, effective October 19, 2026. While framed positively as a "milestone," this is a material transfer of listing venue that reflects the company's achievement of compliance with the higher tier's "more stringent financial and liquidity standards." The reverse of this event—failure to maintain listing standards—would constitute delisting risk; the uplisting itself is the favorable resolution of that risk and is material to investors assessing the company's market standing and capital access.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-10-19
EX-99.1
The exhibit discloses results of an extraordinary general meeting held on October 19, 2026, where shareholders voted to approve a merger agreement between Perfect Corp. and ProjectNY (controlled by Ms. Alice H. Chang). The disclosure reports that approximately 99.99% of votes cast approved the Merger Agreement and related transactions, with 87.4% of voting power represented. This is a material shareholder vote result on a transformative M&A transaction that would result in the Company becoming privately held.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-10-19
Item 8.01
Marker Therapeutics announced receipt of a $2.6 million FDA Orphan Products Development Grant to advance its lead investigational MAR-T cell therapy, MT-601, in pancreatic cancer. This is a material operational and strategic milestone—non-dilutive funding from a highly competitive federal program that validates the scientific rationale of the company's platform and supports clinical development. While not fitting a specific named event type, this clearly represents a material operational/strategic achievement that would affect a reasonable investor's assessment of the company's development trajectory and funding position.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-10-19
Item 7.01
ArriVent announced the publication of Phase 1b clinical trial results for firmonertinib in Cancer Cell, highlighting efficacy and safety data in EGFR PACC-mutant NSCLC. This is a material clinical milestone for a clinical-stage biopharmaceutical company—the publication of positive Phase 1b data supporting advancement toward Phase 3 trials represents a significant operational and strategic development. While not a traditional earnings release, M&A activity, or governance event, this clinical publication is material to investors assessing the company's pipeline progress and therapeutic potential.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 96%
filed 2026-10-19
Item 5.02
Daniel E. Brown was appointed as President and Chief Executive Officer of Expand Energy Corporation, effective October 26, 2026, and concurrently elected to the Board. The appointment includes compensatory arrangements comprising a base salary of $1,000,000, annual bonus target of 125%, long-term incentive awards of $8,750,000 annually, and a make-whole equity award of approximately $15.65 million.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-10-19
Item 1.01
Dogwood Therapeutics entered into a Subscription Agreement to issue 4,098,360 shares of common stock at $1.22 per share in a private placement with Sealbond (a subsidiary of CK Life Sciences), raising approximately $5 million. The unregistered shares are sold under Section 4(a)(2) of the Securities Act and Regulation D, materially diluting existing shareholders' ownership and representing a significant capital raise for the development-stage biopharmaceutical company.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-10-19
EX-99.1
This exhibit announces positive Phase 3 clinical trial results for efgartigimod (VYVGART Hytrulo) in autoimmune myositis, specifically meeting its primary endpoint with a 15.4-point improvement in Total Improvement Score versus placebo at Week 52 (p=0.0011). The announcement discloses that results will be presented as a late-breaking oral presentation at ACR Convergence 2026. While this is a clinical milestone rather than a discrete earnings release, M&A activity, or governance event, it represents material operational/clinical progress for a biopharmaceutical company's pipeline that would affect investor assessment of the registrant's prospects and competitive position in the autoimmune disease market.
View raw filing on EDGAR →
8-K
Governance Other
confidence 75%
filed 2026-10-19
Item 7.01
ConnectM announced the formation of a Strategic Advisory Board and appointed three members (Ashish Kulkarni, Neil Bhatia, and Jim McCabe) to advise on AI energy infrastructure expansion, institutional investor relationships, strategic partnerships, and capital allocation. This is a governance event involving board-level appointments and advisory structure, but does not fit the specific categories of exec_appointment (these are advisory board members, not officers or directors of the company) or exec_compensation. The disclosure is material as it signals strategic leadership changes and investor positioning efforts relevant to the company's growth trajectory.
View raw filing on EDGAR →
6-K
Auditor Change
confidence 98%
filed 2026-10-19
EX-99.1
The exhibit announces that Canaan Inc. engaged KPMG LLP in Singapore as its independent auditor effective October 19, 2026, replacing KPMG Huazhen LLP. The disclosure explicitly states the change was approved by the Audit Committee and Board, and confirms that KPMG Huazhen's prior audit reports contained no adverse opinions, disclaimers, or qualifications, and there were no disagreements or reportable events. This is a clear auditor change event under Item 4.01 of Regulation S-K, material to investors assessing the registrant's financial reporting oversight.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-10-19
Item 1.01
The filing discloses entry into material definitive agreements in connection with the issuance of asset-backed securities by Ford Credit Floorplan Master Owner Trust A. While this is structured as a securitization rather than a traditional M&A transaction, Item 1.01 is being used to report the transaction documents, and the creation of a trust and issuance of notes represents a material capital structure event. The securitization involves a substantive restructuring of assets and creation of new financial instruments, which falls within the scope of material definitive agreements under Item 1.01.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-10-19
Item 1.01
Ford Credit Floorplan Corp has entered into material definitive agreements in connection with the issuance of asset-backed securities by a trust. While this is technically a securitization transaction rather than a traditional M&A activity, it represents a material capital-raising event involving the creation of a new financial structure and transfer of assets to a trust. The securitization of floorplan receivables is a significant financing transaction that would materially affect investor assessment of the registrant's capital structure and liquidity.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-10-19
Item 1.02
The filing discloses termination of a material license agreement (Grünenthal License) and related consent agreement following a settlement of patent litigation. The Company paid $17 million to resolve all disputes, obtained assignment of patents related to Nucynta Products, and eliminated all future royalty obligations. While Item 1.02 addresses termination of material agreements, the substance here—settlement of litigation, patent assignment, and elimination of ongoing royalty obligations—constitutes a material restructuring of the Company's rights and obligations regarding a key product line (Nucynta), warranting classification as a material transaction or settlement activity rather than a routine agreement termination.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-10-19
Item 2.02
RLI Corp. disclosed its third quarter 2026 financial results on October 19, 2026, reporting net earnings of $81.0 million ($0.88 per share) versus $124.6 million ($1.35 per share) in Q3 2025, along with comprehensive financial tables and segment performance metrics. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, with detailed income statement data, per-share metrics, and operational highlights.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-10-19
Item 8.01
Metropolitan Bank Holding Corp. declared a quarterly cash dividend of $0.40 per share, representing a $0.05 increase from the prior quarterly dividend of $0.35 per share, payable on November 10, 2026. This is a clear dividend distribution event that would be material to shareholders and investors assessing the company's capital allocation and shareholder returns policy.
View raw filing on EDGAR →
8-K
Governance Other
confidence 75%
filed 2026-10-19
Item 8.01
Steel Dynamics announced six senior leadership promotions effective October 1 and November 1, 2026, including promotions of Chad Bickford, Jeff Hansen, and William Scruggs to Senior Vice President roles, and appointments of Daniel Keown, Yury Krotov, and Dominic Freiburger to Vice President positions. While these are governance-related executive appointments and promotions, they do not fit the specific `exec_appointment` category (which typically applies to new hires or election to board/C-suite roles) or `exec_departure`. The press release emphasizes these are internal promotions supporting "long-term growth and operational excellence" and talent development, making this a governance restructuring event that is material to investors' understanding of leadership continuity and strategic direction.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-10-19
Item 8.01
The Company disclosed that a previously approved Charter Amendment designed to protect NOL and NCL tax benefits through transfer restrictions lacked the requisite stockholder vote under Maryland law. The Board intends to re-seek stockholder approval for the amendment, which would materially affect shareholder rights and stock transferability.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-10-19
Item 1.01
Curis entered into a Securities Purchase Agreement on October 16, 2026, for the sale of 16,666,680 shares of common stock (or pre-funded warrants) plus common warrants to purchase an additional 16,666,680 shares at an effective combined price of $0.51 per share, generating approximately $8.5 million in gross proceeds. The unregistered securities were sold to institutional accredited investors and qualified institutional buyers pursuant to Section 4(a)(2) exemption, and the company also amended existing warrants to reduce their exercise price.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-10-19
Item 2.02
First United Corporation issued a press release on October 19, 2026, announcing third quarter 2026 financial results with consolidated net income of $7.2 million ($1.11 per diluted share) for Q3 2026 and $19.5 million ($3.01 per diluted share) for the nine-month period ended September 30, 2026, along with detailed financial metrics and management commentary.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-10-19
Item 2.02
The filing discloses Permianville Royalty Trust's announcement of a monthly cash distribution of $0.015000 per unit payable on November 13, 2026. This is a routine but material periodic distribution to unitholders, which is the primary business purpose of a royalty trust. The press release provides detailed information on underlying production volumes, commodity prices, and the calculation basis for the distribution.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 80%
filed 2026-10-19
Item 5.02
Ball Corp appointed Carey Causey as President of Beverage Packaging North and Central America (effective immediately) and Scott A. Vail as President of Beverage Packaging EMEA (effective January 1, 2027), both to senior vice president roles leading major business units.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-10-19
Item 2.01
Service Properties Trust completed the sale of three hotels for $19.0 million on October 15, 2026, pursuant to a previously entered purchase and sale agreement. The filing explicitly states these three hotels "constitute a significant disposition for purposes of Item 2.01," which is the standard Item for material acquisitions and dispositions. This is a material asset disposition event.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 90%
filed 2026-10-19
Item 1.01
ConnectM Technology Solutions closed a Securities Purchase Agreement on October 13, 2026, issuing a Senior Secured Convertible Promissory Note (Two-B) with a principal amount of $1,388,888.89 and purchase price of $1,250,000.00 to Ascent Partners Fund LLC. The note bears 10% interest, matures October 13, 2027, and is part of an aggregate issuance of approximately $5,000,000 under the Purchase Agreement.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-10-19
Item 3.02
ConnectM Technology Solutions conducted an unregistered sale of equity securities embedded in the convertible Note Two-B under Section 4(a)(2) and Regulation D Rule 506 to an accredited investor, representing a private placement with dilutive conversion rights.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-10-19
Item 2.02
SmartFinancial issued a press release on October 19, 2026, reporting third-quarter 2026 earnings results with net income of $18.6 million ($1.10 per diluted share), compared to $13.7 million ($0.81 per share) in Q3 2025. The disclosure includes detailed financial metrics and an investor slide presentation for the earnings conference call on October 20, 2026.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 85%
filed 2026-10-19
Item 8.01
The filing discloses a shareholder complaint (Garfield v. Eglin, Index No. 655801/2026, filed Oct. 9, 2026) seeking to enjoin the Merger and void shareholder approval, plus fourteen demand letters alleging disclosure deficiencies in the proxy statement. While the Company denies merit and voluntarily supplements disclosures to minimize litigation burden, the existence of active litigation challenging a material transaction (the Merger) and seeking injunctive relief is a material legal event that would affect a reasonable investor's assessment of transaction risk and timing.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-10-19
EX-99.1
Goldgroup completed a strategic investment in Luca Mining Corp. by acquiring 101,123,662 subscription receipts (convertible to common shares) for C$101.1 million, representing approximately 19.9% ownership of Luca on a non-diluted basis. The investment is explicitly tied to Luca's proposed acquisition of the Cozamin Mine and includes investor rights including board nomination rights. This constitutes a material acquisition/investment activity under the M&A taxonomy, as Goldgroup is acquiring a significant equity stake in another mining company as part of its stated M&A strategy.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 92%
filed 2026-10-19
Item 5.07
Shareholders approved an extension of the deadline for completing an initial business combination from October 24, 2026 to July 24, 2027, with 19,248,978 votes in favor and 1,628,247 against. The vote also approved an amendment to the Investment Management Trust Agreement extending the trust account liquidation deadline to July 24, 2027. Approximately 78.66% of Class A shares were redeemed at $10.58 per share, withdrawing approximately $187.3 million from the trust account.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-10-19
Item 7.01
This Item 7.01 disclosure furnishes supplemental Q&A documentation regarding a previously announced proposed sale of Barnwell's Canadian oil and natural gas business to a local Canadian corporation. The transaction, signed October 5, 2026, involves a material disposition of a business segment for C$9 million in base consideration plus a retained royalty. The Q&A clarifies key transaction terms including purchase price, royalty mechanics, closing conditions, and shareholder implications. This is supplemental disclosure of a material acquisition/disposition event (ma_activity), consistent with the prior Form 8-K filed October 6, 2026.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-10-19
Item 1.01
Enerpac entered into an Amended and Restated Credit Agreement on October 16, 2026, replacing its prior $625 million revolving facility and $200 million term loan with a new $550 million revolving facility and $300 million term loan, maturing in 2031. This material refinancing modifies the company's debt structure, terms, covenants, and maturity dates, affecting its financial obligations and liquidity profile.
View raw filing on EDGAR →
8-K
Financial Other
confidence 75%
filed 2026-10-19
Item 1.01
Medallion Financial entered into a Purchase and Settlement Agreement to repurchase $15 million in trust preferred securities (TruPS) for $11.049 million (73.66% discount to face value), with an ancillary five-year standstill agreement with ZimCal. The company expects to record a gain in Q4 2026 and characterizes the transaction as accretive to common shareholders.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-10-19
Item 8.01
The filing discloses material regulatory approvals for a previously announced merger: the European Commission's unconditional approval on October 15, 2026, and the New York Public Service Commission's declaratory ruling on October 19, 2026. These are significant milestones in the completion of the merger with Horizon Parent, L.P., which will result in the Company being jointly owned by investment vehicles affiliated with Global Infrastructure Management, LLC and EQT Infrastructure VI fund. This represents a material acquisition/change of control event.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-10-19
Item 5.02
CarMax appointed Darren W. Woodell as Vice President, Controller and Chief Accounting Officer, effective November 11, 2026, assuming the principal accounting officer role from Enrique N. Mayor-Mora. The disclosure centers on the appointment of a named executive to a material officer position (principal accounting officer), making this an exec_appointment event. The compensation details provided are incidental to the primary action of taking the role.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-10-19
EX-99.1
This press release announces three-year clinical trial data for EVX-01, Evaxion's lead personalized cancer vaccine candidate in advanced melanoma. The disclosure reports sustained clinical responses with no tumor progression at three-year follow-up, building on prior two-year data showing 75% objective response rate. While this is a clinical milestone for a development-stage biotech company, it does not fit the discrete event categories (no earnings release, M&A, executive change, or restatement). The data announcement is material to investors assessing the company's pipeline progress and partnership potential, as noted in the CSO's statement regarding "potential partnership discussions."
View raw filing on EDGAR →
6-K
Earnings release
confidence 85%
filed 2026-10-19
EX-99.1
This exhibit announces Golar LNG's Q3 2026 results release scheduled for November 18, 2026, with details on the webcast and conference call presentation. Although the actual financial results are not yet disclosed in this document, the announcement of a quarterly earnings release and investor presentation is a material event that would affect a reasonable investor's assessment of the company's performance and financial condition.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-10-19
EX-99.1
BrainsWay announced a strategic collaboration with Inland Psychiatric Medical Group involving a multisystem order of Deep TMS systems and exploration of joint scientific and clinical research projects. This is a material operational/commercial partnership that expands the company's market reach and clinical applications, but does not fit the specific categories of M&A activity, debt issuance, or other defined event types. The collaboration represents a significant business development milestone for a medical device company seeking to accelerate adoption of its neurostimulation platform.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-10-19
EX-99.1
Rubico announced a registered direct offering of $8.5 million in senior convertible notes and warrants to a single institutional investor. The offering includes convertible notes with a 12-month maturity, warrants exercisable for 25,903,577 common shares at $0.3646 per share, and commitment shares of 1,295,179 shares. This is a dilutive equity issuance raising capital through convertible securities and warrants, which would significantly dilute existing shareholders and is material to investors assessing the company's capital structure and ownership.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-10-19
Item 2.02
ServisFirst Bancshares issued a press release on October 19, 2026, announcing third quarter 2026 operating results, including diluted earnings per share of $0.80 (up 33% year-over-year), net income of $87.3 million, loan growth of 11% year-over-year, and an efficiency ratio of 30.20%.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-10-19
Item 2.02
This is a clear earnings release for Q3 2026. The Item 2.02 disclosure announces consolidated financial results for the third quarter 2026, with a press release titled "Muncy Columbia Financial Corporation Announces Third Quarter 2026 Earnings" attached as Exhibit 99.1. The press release contains detailed unaudited financial statements (balance sheet, income statement, and operating highlights) showing net income of $6,043,000 ($0.57 per share) for Q3 2026 versus $6,719,000 ($0.63 per share) for Q3 2025, along with comprehensive financial metrics and management discussion of results.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-10-19
Item 5.02
Robert E. Hoffman was appointed Chief Executive Officer of CytoDyn effective October 20, 2026, following Board approval on October 16, 2026, replacing Dr. Jacob Lalezari who transitioned to Head of Research and Translational Sciences. The appointment includes significant compensation changes, including a base salary increase to $525,000, bonus target increase to 50%, and a 2.5 million share option grant, representing a material executive leadership transition for the clinical-stage biopharmaceutical company.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-10-19
EX-99
This exhibit announces a $235 million contract award to supply EXTRA-MR rockets and PULS launchers to a European customer over three years. While the contract is material in size and represents a significant operational win for Elbit Systems' defense business, it does not fit the discrete event categories (not M&A, not a financial obligation like debt issuance, not a restructuring). The disclosure is a material contract/business development announcement—a strategic operational event that strengthens the company's market position and backlog, making it operational_other rather than a routine administrative matter.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-10-19
EX-99.1
RedHill announced that its partner University of Oklahoma received a $2.9 million National Cancer Institute grant to fund clinical trials (Phase 1b and Phase 2) evaluating opaganib in combination with CAR T-cell therapy for ultra-high-risk multiple myeloma. This is a material operational and strategic milestone—a significant government-backed research collaboration that advances the clinical development of a key pipeline asset (opaganib) and demonstrates external validation of the company's therapeutic approach. While not a discrete M&A transaction, debt issuance, or earnings event, it represents a material operational development that would affect a reasonable investor's assessment of RedHill's pipeline progress and partnerships.
View raw filing on EDGAR →